Achillion Pharmaceuticals, Inc. (ACHN)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
8.10+0.17 (+2.14%)
At close: 4:00 PM EDT
People also watch:
FOLDACADARIACLDXARRY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open7.98
Prev Close7.93
Bid7.00 x 100
Ask8.27 x 100
Day's Range7.89 - 8.14
52wk Range5.57 - 10.95
1y Target EstN/A
Market Cap1.11B
P/E Ratio (ttm)165.31
Beta2.21
Volume957,321
Avg Vol (3m)1,433,428
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Hey Gilead, It's Time to Start Looking Over Your Shoulder in Hepatitis C
    Motley Fool21 hours ago

    Hey Gilead, It's Time to Start Looking Over Your Shoulder in Hepatitis C

    This dynamic duo appears to be on track to give Gilead's portfolio of hepatitis C products a run for its money.

  • Achillion Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ACHN) : September 27, 2016
    Capital Cube4 days ago

    Achillion Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ACHN) : September 27, 2016

    Categories: Fundamental Analysis Yahoo Finance Click here to see latest analysis Capitalcube gives Achillion Pharmaceuticals, Inc. a score of 43. Our analysis is based on comparing Achillion Pharmaceuticals, Inc. with the following peers – Vertex Pharmaceuticals Incorporated, Gilead Sciences, Inc., Bristol-Myers Squibb Company, NanoViricides, Inc., GlaxoSmithKline plc Sponsored ADR, Enanta Pharmaceuticals, Inc., Johnson & Johnson, Neogen Corporation, Merck & Co., ... Read more (Read more...)

  • Achillion, J&J HCV Triple Combination Drug Data Presented
    Zacks5 days ago

    Achillion, J&J HCV Triple Combination Drug Data Presented

    Achillion Pharmaceuticals, Inc. (ACHN) presented updated interim results from a phase II study on a triple combination of AL-335, odalasvir and Johnson & Johnson???s (JNJ) Olysio (simeprevir) at the European Association.